镰状细胞病患儿接受匹配同胞供者异基因造血干细胞移植前基于白消安-氟达拉滨或曲奥舒凡-氟达拉滨的预处理:代表EBMT儿科疾病与先天性疾病工作组的研究
该研究基于EBMT登记库比较2010-2020年间251例18岁以下镰状细胞病患儿接受首次匹配同胞供者造血干细胞移植时,采用白消安-氟达拉滨(bu-flu,n=89)或曲奥舒凡-氟达拉滨(treo-flu,n=162)预处理方案的结局。两组2年总生存率分别为98.7%与99.3%(p=0.63),III-IV级急性GVHD发生率分别为2.4%与0.6%(p=0.25),广泛型慢性GVHD 2年发生率分别为1.5%与8.0%(p=0.057)。数据证实清髓性预处理下匹配同胞供者移植具有极好治愈能力,两种方案均获得优异总生存、低急慢性GVHD率和低植入失败率。
要点
- 2年总生存率bu-flu组98.7% vs treo-flu组99.3%(p=0.63)
- 100天III-IV级急性GVHD发生率bu-flu组2.4% vs treo-flu组0.6%(p=0.25)
- 2年广泛型慢性GVHD发生率bu-flu组1.5% vs treo-flu组8.0%(p=0.057)
核心结论
- 这些跨国数据证实采用清髓性预处理的匹配同胞供者造血干细胞移植对镰状细胞病具有极好治愈能力。
- 两种预处理方案均获得优异总生存、低急性和慢性GVHD发生率以及低植入失败率。
研究设计与样本
- 基于EBMT登记库的比较研究,纳入2010-2020年间251例年龄小于18岁的镰状细胞病患者,均接受首次匹配同胞供者造血干细胞移植。
- 预处理方案为白消安-氟达拉滨(bu-flu;n=89)或曲奥舒凡-氟达拉滨(treo-flu;n=162)。
- bu-flu组和treo-flu组分别有51.7%和99.4%的患者接受了塞替派。
- 中位随访时间为2.7年。
主要发现
- 2年总生存率bu-flu组为98.7%(95%CI:90.9-99.8),treo-flu组为99.3%(95%CI:95.2-99.9)(p=0.63)。
- 100天III-IV级急性GVHD发生率bu-flu组为2.4%(95%CI:0.4-7.5),treo-flu组为0.6%(95%CI:0.1-3.2)(p=0.25)。
- 2年广泛型慢性GVHD发生率bu-flu组为1.5%(95%CI:0.1-7.3),treo-flu组为8.0%(95%CI:4.1-13.3)(p=0.057)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
How important is choice of conditioning regimen in allogeneic haematopoietic stem cell transplantation (HSCT) for sickle cell disease (SCD)? We compared HSCT outcomes by conditioning regimen in paediatric patients with SCD from the EBMT registry. In 2010-2020, 251 patients aged <18 years underwent a first matched sibling donor (MSD) HSCT with conditioning based on busulfan-fludarabine (bu-flu; n = 89) or treosulfan-fludarabine (treo-flu; n = 162). In the bu-flu and treo-flu groups, 51.7% and 99.4% of patients, respectively, received thiotepa. Median follow-up was 2.7 years. Two-year overall survival (OS) was 98.7% (95% confidence interval [CI]: 90.9-99.8) with bu-flu and 99.3% (95% CI: 95.2-99.9) with treo-flu (p = 0.63). Grade III-IV acute graft-versus-host disease (GVHD) at 100 days was 2.4% (95% CI: 0.4-7.5) and 0.6% (0.1%-3.2%) for bu-flu and treo-flu respectively (p = 0.25). The 2-year incidence of extensive chronic GVHD was 1.5% (95% CI: 0.1-7.3) with bu-flu and 8.0% (95% CI: 4.1-13.3) with treo-flu (p = 0.057). These multinational data confirm the excellent curative capacity of MSD HSCT with myeloablative conditioning. Both conditioning regimens yielded excellent OS, low rates of acute and chronic GVHD, and low rates of graft failure.
引用
- Cseh A, Galimard JE, de la Fuente J, et al. Busulfan-fludarabine- or treosulfan-fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties. Br J Haematol. 2023. PMID: 37795523. doi:10.1111/bjh.19122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。